Llach, J., Gines, P., Arroyo, V., et al. (1988) Prognostic Value of Arterial Pressure, Endogenous Vasoactive Systems, and Renal Function in Cirrhotic Patients Admitted to the Hospital for the Treatment of Ascites. Gastroenterology, 94, 482-487.
https://doi.org/10.1016/0016-5085(88)90441-6

has been cited by the following article:

• TITLE: The Effect of Loop Diuretics on Sarcopenia and Long-Term Prognosis in Patients with Refractory Hepatic Ascites Treated with Tolvaptan

  AUTHORS: Masaaki Shimada, Hiroaki Iwase, Noboru Hirashima, Masashi Saito, Hisashi Kondo, Noboru Urata, Satoshi Unita, Takashi Kondo, Daiki Tanaka, Takuya Tsunekawa

  KEYWORDS: Tolvaptan, Hepatic Ascites, Sarcopenia, Loop Diuretics, Long-Term Prognosis

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.8 No.6, June 14, 2018

  ABSTRACT: We investigated sarcopenia, focusing on the dose of loop diuretics used in 70 patients with refractory hepatic ascites treated with tolvaptan. Bloating improved in 68.5% of patients, as determined using the Japanese version of the Support Team Assessment Schedule. The psoas muscle index (PMI) was used to define sarcopenia. A statistically significant difference was observed in the PMI between patients receiving low-dose (3.6 ± 1.2 cm2/m2) and high-dose furosemide (3.1 ± 1.2 cm2/m2) before tolvaptan treatment (P = 0.048). The PMI increased from 3.2 ± 1.1 cm2/m2 to 3.5 ± 1.3 cm2/m2 (P = 0.002) in responders, but decreased from 3.4 ± 1.2 cm2/m2 to 3.0 ± 1.0 cm2/m2 (P = 0.106) in non-responders before and after tolvaptan treatment, respectively. The long-term prognosis improved in responders compared with non-responders (mean survival time: 646 days vs. 228 days, P